Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
The Latest on: Liver diseases
via Google News
The Latest on: Liver diseases
- Asia's first 'live' liver donor, having six stents, undergoes high risk beating heart bypass surgeryon October 7, 2020 at 2:24 am
If a liver donor later develops complex heart disease, like in this patient, he can still undergo a high-risk bypass surgery successfully with an experienced team of doctors. Hence patients who have ...
- Butler County woman fighting two chronic diseases now searching for living liver donoron October 6, 2020 at 7:20 pm
The Mayo Clinic describes Crohn’s as an “inflammatory bowel disease” that can cause a number of symptoms, including pain, fatigue and malnutrition. On top of that, Griffin says she has a liver disease ...
- Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting Digital Experience™ 2020on October 6, 2020 at 6:00 am
PRNewswire/ -- Sagimet Biosciences, a clinical-stage biotechnology company, announced today that new results from its Phase 2 FASCINATE-1 trial of TVB-2640 ...
- Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting Digital Experience(TM) 2020on October 6, 2020 at 6:00 am
Sagimet Biosciences, a clinical-stage biotechnology company, announced today that new results from its Phase 2 FASCINATE-1 trial of TVB-2640 in nonalcoholic steatohepatitis ...
- Sidra Medicine transforms lives of children with liver diseaseson October 5, 2020 at 9:34 am
The Liver Clinic at Sidra Medicine has transformed the lives of hundreds of young children in Qatar with complex liver diseases, including 40 sent overseas for liver transplantations.
- Salix Supports Liver Awareness Month With New Educational Initiativeson October 5, 2020 at 4:00 am
Educational Online Resource Offers Tools for Early Detection of Overt Hepatic Encephalopathy in Chronic Liver Disease Patients ...
- North America Liver Disease Treatment Market Expected to Reach $8.31 Billion by 2027on September 30, 2020 at 10:24 pm
According to a new report published by Allied Market Research, titled, "North America Liver Disease Treatment Market by Treatment Type, and Disease Type: Opportunity Analysis and Industry Forecast, ...
- Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conferenceon September 30, 2020 at 4:02 am
Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases ...
- Global Liver Institute Urges Congress to Strengthen and Support Public Health Programs Serving those with Liver Cancer and Liver Diseaseon September 29, 2020 at 5:30 am
As Liver Cancer Awareness Month approaches, the Global Liver Institute (GLI) is appealing to Congress to act now to secure the health ...
- GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Diseaseon September 28, 2020 at 12:00 am
Innovative multi-biomarker blood test based on GENFIT’ S NIS4™ technology is specifically designed to identify patients with at-risk non-alcoholic steatohepatitis LabCorp to commercialize the test for ...
via Bing News